Based on this concept, our results suggest that ESO-specific CD4+ T cells induced through immunization of cancer patients with the rESO vaccine are likely to be not only quantitatively but also qualitatively superior to those arising during spontaneous immune responses, which further encourages the use of ESO-based vaccines in patients bearing ESO-expressing tumors. The gene discussed is CD4; the disease is cancer.